Radiation therapy is afflicted by a multitude of geometric uncertainties, which must be compensated to ensure treatment success. Such mitigation is currently achieved by enlarging the apparent target volume by various safety margins. This thesis investigated uncertainty sources relating to target position and extent in oesophageal carcinoma, both static and dynamic, and evaluated their impact in a combined model. The first were errors inherent to delineation of the gross tumour volume (GTV), where computed tomography (CT) imaging, the overall modality of choice for target volume delineation (TVD), has a tendency to overestimate target extent. Two rival modalities, [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) and endoscopic ultrasound (EUS), are generally expected to yield more accurate assessments. EUS has previously suffered from a difficulty in transferring its findings to the spatial domain in which TVD is undertaken. This limitation was overcome here through the use of endoscopically implanted fiducial markers visible on the planning CT. This has enabled their inclusion in TVD and allowed a direct comparison of FDG-PET and EUS based target extents, which were found to agree quite well on average, but showed occasional discrepancies on the order of a few cm. Recently published reports on inter-observer variability (IOV) in TVD of oesophageal carcinoma were summarised with a particular focus on its reduction afforded by the use of fiducial markers. The influence of IOV was investigated more widely in other tumour entities, where it was shown to increase during the course of treatment, mostly due to differing adaptation practices. Microscopic disease extension (MDE), undetectable prior to treatment with current imaging techniques, constituted the second uncertainty source. Reports on histopathological measurements of MDE incidence and its distance from the main tumour were reviewed and spatial measurements extracted to derive a combined estimate of the distribution of extension distances. The overall incidence was estimated as 14.6%, with individual studies reporting widely differing values. Conventional margin widths to compensate for MDE were extracted from the pooled distribution and found to largely agree with the common clinical choice of 3–5 cm, but associated with broad confidence intervals. The addition of such margins to the GTV defines the clinical target volume (CTV). Most studies acknowledged tissue deformations as a major problem, but not all implemented means to prevent or correct it. Preliminary measurements on oesophageal resection specimens were presented, wherein fiducial markers were used to measure tissue deformations, and might ultimately be used to correct spatial measurements of MDE. Fiducial markers also facilitated the study of inter-fractional target mobility in a cohort (n=23) receiving daily orthogonal X-ray imaging for target positioning verification. Markers were found capable of detecting target misalignments, which were a common occurrence with 54% and 15% of analysed markers and treatment fractions showing displacements from their planned position in excess of 5 and 10mm, respectively. Mobility amplitudes were highest in the longitudinal direction and a dependence on tumour location was hinted at, with motion more restricted for proximally located lesions. Measures of systematic and random mobility components were extracted to derive safety margins, which are added to the CTV to form the planning target volume (PTV). A radiobiological model of tumour control probability (TCP) was then evaluated under different uncertainty scenarios. It simplified the tumour system to its longitudinal dimension, which is most affected by the aforementioned phenomena, and simulated positional uncertainties, as well as MDE. The differential impact of systematic and random mobility components on TCP was demonstrated and margin widths sufficient to limit TCP reduction to 1% could best be described by a quadratic combination of their magnitudes. This composition was still applicable when MDE was introduced and mitigated by a conventional margin, but the relative impact of both components shifted. The addition of a PTV margin to the CTV afforded the MDE-positive subpopulation similar protection against positional uncertainties as the same margin achieved without consideration of MDE. The MDE-negative subpopulation attained a much improved tolerance to positional uncertainties through the CTV margin, which also propagated to the overall population. An alternative mitigation of MDE was attempted by optimising the applied dose distribution to an assumed tumour cell density distribution motivated by the literature, which decreases towards the target edge. The optimisation maximised TCP while preserving the integral dose delivered with a conventional margin, under the assumption that this translates into a similar likelihood of normal tissue toxicity. Reduced doses could be delivered to lower cell density regions without sacrificing overall TCP, but this reduction was modest despite vastly diminished cell densities. When this spared dose was redistributed so as to enlarge the treated area, negligible TCP change was observed, but redistribution to the central target did result in appreciably improved TCP in both subpopulations. These effects persisted when positional uncertainties were added and when MDE incidence was increased to the most extreme value reported in the literature.

A esquistossomose é uma doença causada por trematódeos do gênero Schistosoma. Dentre os genes identificados no transcriptoma do parasita, membros da família gênica SmVAL (Schistosoma mansoni Venom Allergen-Like) foram apontados como candidatos vacinais. SmVALs foram identificadas em secreções de cercárias e esquistossômulos cultivados in vitro, os transcritos SmVAL4 e 24 foram localizados nas glândulas acetabulares de germ ball e a proteína nativa SmVAL4 foi identificada em extrato de cercárias, indicando funções durante a penetração da pele. Já os transcritos SmVAL13 e 14 foram localizados na glândula esofágica anterior de vermes adultos, sugerindo papéis no processo de alimentação sanguínea. A imunização com as proteínas rSmVAL4, 6, 7, 13, 14 e 18 coadministradas não protegeu camundongos contra o desafio experimental, porém, observou-se uma diminuição do número de fêmeas e do número de ovos no grupo imunizado. A investigação de funções para as proteínas secretadas mostrou que a rSmVAL18 interage com plasminogênio in vitro favorecendo a invasão do hospedeiro. / Schistosomiasis is a disease caused by trematodes of the genus Schistosoma. Among the genes identified in the parasite transcriptome, members of SmVAL (Schistosoma mansoni Venom Allergen-Like) gene family were proposed as vaccine candidates. SmVALs were identified in cercariae and schistosomule secretions in vitro, the SmVAL4 and 24 transcripts were located to the germ ball acetabular glands and SmVAL4 native protein was identified in cercariae extract, indicating functions in skin penetration. On the other hand, SmVAL13 and 14 transcripts were located to the anterior esophageal gland of adult worms, suggesting roles in the blood feeding processes. Immunization with rSmVAL4, 6, 7, 13, 14 and 18 proteins co-administered did not protected mice against experimental challenge, however, there was a decrease in the number of females and the number of eggs in the immunized group. The investigation of functions for secreted proteins showed that rSmVAL18 interacts with plasminogen in vitro thus favoring the host invasion.

Oesophageal cancer is a malignant and aggressive disease with very poor survival. The aim of this thesis was to evaluate novel therapeutic targets in oesophageal cancer. In paper I, Hsp90 was expressed in all 81 oesophageal cancer tissues and also in nine oesophageal cancer cell lines. A specific Hsp90 inhibitor, 17-AAG, could efficiently inhibit cell proliferation, cell survival and sensitise oesophageal cancer cells to gamma photon irradiation. By inhibition of Hsp90 using 17-AAG, EGFR- and IGF-1R-mediated signalling was downregulated. In paper II, tumour samples from 80 oesophageal cancer patients were investigated for the expression of EGFR and LRIG1-3. Based on a total score of intensity and expression fraction a trend towards survival differences was found for LRIG2 (p=0.18) and EGFR (p=0.09). Correlation analysis revealed a correlation between expression of EGFR and LRIG3 (p=0.0007). Significant correlations were found between LRIG1 mRNA expression levels and sensitivity to cisplatin (r = –0.74), docetaxel (r = –0.69), and vinorelbine (r = –0.82). In paper III, microtubule targeting drugs podophyllotoxin (PPT), vincristine and docetaxel inhibited survival and proliferation of oesophageal cancer cells. Unexpectedly, experiments showed that microtubule destabilising agents inhibited EGFR phosphorylation and signalling. A tyrosine phosphatase inhibitor, sodium orthovanadate, was able to reverse the EGFR dephosphorylation. In paper IV, imetelstat, a telomerase antagonist, inhibited telomerase activity, colony formation ability and decreased proliferation of oesophageal cancer cells. Inhibition of telomerase activity by imetelstat led to an increase of 53BP1 foci indicating induction of DSBs. Furthermore, the fraction and size of radiation-induced 53BP1 foci were increased by imetelstat pre-treatment. In conclusion, Hsp90 and telomerase represent potential therapeutic targets in oesophageal cancer. And, the implication of EGFR and LRIG as prognostic factors is limited. Furthermore, disruption of the microtubule network may activate a protein tyrosine phosphatase that can regulate EGFR phosphorylation.

Chez l’enfant, l’insuffisance respiratoire aiguë est responsable de la majeure partie des admissions en soins intensifs. La population pédiatrique étant marquée par une grande hétérogénéité en termes d’âge, de pathologie respiratoire et de maturation pulmonaire, une individualisation de la prise en charge thérapeutique est indispensable. Dans ce contexte, différents outils sont disponibles pour évaluer de manière plus objective le travail respiratoire du patient en insuffisance respiratoire aiguë. Objectifs - Le principal objectif de la thèse est d’évaluer l’intérêt diagnostique et thérapeutique de la mesure du travail respiratoire dans l’insuffisance respiratoire aiguë hypercapnique de l’enfant.Méthodes - Trois principaux outils d’évaluation du travail respiratoire ont été utilisés dans nos travaux : la mesure des pressions œsogastriques, la mesure de l’activité électrique du diaphragme et la mesure de la consommation en oxygène par la calorimétrie.Résultats - Nous avons pu mettre en évidence les intérêts de ces outils de mesure aux différents stades d’évolution de la maladie : (i) à la phase initiale pour indiquer l’initiation d’une ventilation non invasive et pour optimiser ces réglages ; (ii) à la phase d’évolution de la maladie pour évaluer l’interaction patient-ventilateur ; (iii) à la phase de sevrage ventilatoire pour détecter précocement une augmentation du travail respiratoire.Conclusion - Tout au long du processus évolutif de la maladie, la surveillance objective du travail respiratoire peut aider à comprendre les mécanismes de la maladie pulmonaire, optimiser les réglages de l’assistance respiratoire, et adapter les interventions thérapeutiques. / Acute respiratory failure is the leading cause of hospital admissions in the pediatric intensive care unit and is associated with significant morbidity and mortality. Since the pediatric population is characterized by a great heterogeneity in terms of age and respiratory pathology, individualization of therapeutic management is essential. Different minimally invasive methods have been described to assess the patient's work of breathing in acute respiratory failure.Objectives - The main objective of the project was to assess the diagnostic and therapeutic contribution of the measurement of the work of breathing in children with acute hypercapnic respiratory failure.Methods - We used in the present work three tools to assess the work of breathing: oesogastric pressures, electrical activity of the diaphragm monitoring and oxygen consumption measurements.Results - We highlighted how these different methods are valuable during the ICU stay: (i) in the early phase of the disease to initiate or withdraw noninvasive ventilation and to optimize its settings; (ii) in the recovery phase to evaluate the patient-ventilator interaction; (iii) during the weaning process to early detect an increase in work of breathing.Conclusion - Throughout the disease process, the work of breathing assessment can be useful to enhance our understanding of the pathophysiology of lung disease, to optimize mechanical ventilation settings and adapt therapeutic interventions.

The impact was assessed of clinical and nutritional factors on prognosis of 107 oesophageal cancer patients treated with neoadjuvant chemoradiotherapy (CHRT) and surgery. Individualised nutritional support, according to grade of dysphagia was carried out in all the patients. Serum leptin, soluble leptin receptors (SLR), TNF, IGF and fatty acid (FA) profiles in plasma phosphatidylcholine (PC) were studied as well. Addition of paclitaxel to carboplatin and continual fluorouracil significantly increased toxicity without influencing efficacy of the treatment. Post-operative node negativity, grade of dysphagia, weight loss and serum albumin were proved to be prognostic factors of survival and time to progression. CHRT led to decrease of SLR, palmitoleic and oleic acid and increase of n-3 polyunsaturated FA in PC. Lower concentrations of SLR were associated with improved survival of the patients. Key words: oesophageal cancer, neoadjuvant chemoradiotherapy, weight loss, paclitaxel, albumin, soluble leptin receptor, fatty acids

A esquistossomose é uma doença causada por trematódeos do gênero Schistosoma. Dentre os genes identificados no transcriptoma do parasita, membros da família gênica SmVAL (Schistosoma mansoni Venom Allergen-Like) foram apontados como candidatos vacinais. SmVALs foram identificadas em secreções de cercárias e esquistossômulos cultivados in vitro, os transcritos SmVAL4 e 24 foram localizados nas glândulas acetabulares de germ ball e a proteína nativa SmVAL4 foi identificada em extrato de cercárias, indicando funções durante a penetração da pele. Já os transcritos SmVAL13 e 14 foram localizados na glândula esofágica anterior de vermes adultos, sugerindo papéis no processo de alimentação sanguínea. A imunização com as proteínas rSmVAL4, 6, 7, 13, 14 e 18 coadministradas não protegeu camundongos contra o desafio experimental, porém, observou-se uma diminuição do número de fêmeas e do número de ovos no grupo imunizado. A investigação de funções para as proteínas secretadas mostrou que a rSmVAL18 interage com plasminogênio in vitro favorecendo a invasão do hospedeiro. / Schistosomiasis is a disease caused by trematodes of the genus Schistosoma. Among the genes identified in the parasite transcriptome, members of SmVAL (Schistosoma mansoni Venom Allergen-Like) gene family were proposed as vaccine candidates. SmVALs were identified in cercariae and schistosomule secretions in vitro, the SmVAL4 and 24 transcripts were located to the germ ball acetabular glands and SmVAL4 native protein was identified in cercariae extract, indicating functions in skin penetration. On the other hand, SmVAL13 and 14 transcripts were located to the anterior esophageal gland of adult worms, suggesting roles in the blood feeding processes. Immunization with rSmVAL4, 6, 7, 13, 14 and 18 proteins co-administered did not protected mice against experimental challenge, however, there was a decrease in the number of females and the number of eggs in the immunized group. The investigation of functions for secreted proteins showed that rSmVAL18 interacts with plasminogen in vitro thus favoring the host invasion.

The impact was assessed of clinical and nutritional factors on prognosis of 107 oesophageal cancer patients treated with neoadjuvant chemoradiotherapy (CHRT) and surgery. Individualised nutritional support, according to grade of dysphagia was carried out in all the patients. Serum leptin, soluble leptin receptors (SLR), TNF, IGF and fatty acid (FA) profiles in plasma phosphatidylcholine (PC) were studied as well. Addition of paclitaxel to carboplatin and continual fluorouracil significantly increased toxicity without influencing efficacy of the treatment. Post-operative node negativity, grade of dysphagia, weight loss and serum albumin were proved to be prognostic factors of survival and time to progression. CHRT led to decrease of SLR, palmitoleic and oleic acid and increase of n-3 polyunsaturated FA in PC. Lower concentrations of SLR were associated with improved survival of the patients. Key words: oesophageal cancer, neoadjuvant chemoradiotherapy, weight loss, paclitaxel, albumin, soluble leptin receptor, fatty acids

Bypass or resection of the stomach and oesophagus, has long been recognised to result in profound changes in the handling of ingested nutrients. This results in significant morbidity after radical surgery for oesophago-gastric cancer, in particular post-prandial hypoglycaemia, altered appetite, early satiety and noxious post-prandial symptoms. By profiling and challenging the gut hormone axis in healthy volunteers and patients who had undergone total or subtotal gastrectomy, or oesophagectomy, this thesis explores the possible causative mechanisms for the challenges faced by this patient population. In the surgical groups, an oral glucose tolerance test (OGTT) resulted in enhanced secretion of satiety and incretin gut hormones (GLP-1, GIP, PYY) and insulin, followed by hypoglycaemia in a cohort of patients. Continuous glucose monitoring of gastrectomy participants over two weeks of normal lifestyle identified an increased incidence of day and night time hypoglycaemia. RNAseq and mass spectrometry based peptidomics of human and murine enteroendocrine cells in the pre- and post-operative populations revealed no significant change in the underlying cellular pathways for nutrient sensing and gut hormone secretion, indicating that the altered hormone secretion is primarily driven by accelerated nutrient transit, rather than adaptive changes in the gut. Finally, specific blockade of the GLP-1 receptor in post-gastrectomy patients using Exendin 9-39 normalised insulin secretion and prevented reactive hypoglycaemia after an OGTT. In conclusion, profound changes in gut hormone secretion as a result of enhanced nutrient transit after foregut surgery likely underlie the early and late post-prandial symptoms seen in this group, and therapies specifically targeting the gut hormone axis, and GLP-1 in particular, could be the first targeted treatments for post-gastrectomy syndromes.

Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2008.

Acid-related disorders are common, chronic conditions that have considerable impact on a patient's quality of life. In a study conducted by Majumdar et al. (2003:2411) the prevalence of chronic acid-related disorders was 2.3%. Acid-related disorders represent a major financial consideration with respect to the costs of drug prescribing (Whitaker, 1998:6). Health care cost increases each year. This leads to an increased interest in economic evaluation of health care and medical technologies (Anell & Svarvar, 2000:175). Health care providers no longer make treatment decisions independent of the consideration of the resultant cost. The treatment provided must not only provide value but the value must be documented to justify spending money. Economic evaluation research has emerged to offer guidance to policy makers, practitioners, health plans and institutions facing difficult treatment and coverage decisions (Ellis era/., 2002:271). The main objectives of this study were to investigate the prescribing patterns and cost of acid reducing medicine with special reference to proton pump inhibitors and histamine-2 receptor antagonists in a section of the private health care sector of South Africa from 2001 to 2006. A longitudinal retrospective drug utilisation study was done on acid reducing medicine items claimed through a national medicine claims database. The five study years were 2001, 2002, 2004, 2005 and 2006. All the study years stretched from 1 January to 31 December. It was determined that acid reducing medicine items prescribed decreased from 2.74% during 2001 to 2.50% during 2006 of all medicine items claimed. The same decreasing trend was observed regarding the cost of acid reducing medicine items. The cost percentage decreased from 4.89% (2001) to 3.72% (2006). However, the average cost per medicine item for the acid reducers increased by 5.35% from 2001 (R230.04 ± 176.29) to 2002 (R243.72 ± 184.18) and then decreased by 15.23% from 2002 to 2004. It again decreased with 15.05% from 2004 (R206.19 ± 179.42) to 2006 (R175.70 ± 172.55). The changes in the average cost of acid reducers were of no practical significance. Proton pump inhibitors represented about half of the acid reducing medicine items prescribed and more than 70% of the total cost of acid reducing medicine items during the study years. The average cost of PPIs revealed a practical significant decrease (d > 0.8) from 2002 (R372.42 ± 156.62) to 2006 (R241.56 ± 177.21). H2RAs contributed between 15.00% and 18.26% of all acid reducing medicine items while contributing to between 9.68% and 16.85% of the total cost of all acid reducers. The active ingredient most often prescribed was lansoprazole during 2001 and 2002, esomeprazole during 2004 and omeprazole during 2005 and 2006. Lanzor® 30mg was the acid reducer with the highest cost from 2001 to 2005, while Pariet® 20mg took the lead in 2006. Zantac® 150mg effervescent tablets were the H2RA, with the highest cost, during the five study years. The percentage innovator items decreased by 4.50% from 2001 to 2002, increased by 1.01% from 2002 to 2004 and decreased again by 31.06% from 2004 to 2006. The slight increase in the percentage innovator medicine items claimed from 2002 to 2004 may be explained by the introduction of Nexiam® (esomeprazole) into the market in 2002. The total number of generic medicine items claimed contributed between 9.62% (n = R1 788 242.25) in 2001 and 30.75% (n = R3 196 163.34) in 2006 of the total cost of acid reducing medicine items. The average cost per day of innovator medicine items was higher than the average cost per day of generic medicine items. This might be explained by a lower average cost for generic medicine items. It was also determined that the prevalence of the two-drug regimens was the highest during the five study years. The Helicobacter pylori (H.pylori) eradication treatments, which included different antibiotics, increased from 2.72% in 2001 to 5.05% in 2006. The PDD for most of the active ingredients of H2RAs and PPIs remained stable during the study years. However, it appears that the PDDs, of the PPIs, active ingredients were more constant than the PDDs, or the H2RAs, active ingredients. The median of the different PPI active ingredients was reasonably more constant than the median of the different H2RA active ingredients. Thus the changes between the PPIs' and H2RAs' active ingredients might be explained by the variation in the median (the number of days the relevant medicine item was claimed for). It is then also recommended that the aspects of generic substitution as well as the usage of H2RAs as prescribed vs. self medication should be further investigated to increase possible cost savings. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2008.